Interstitial Intensity Modulated Photodynamic Therapy (i-IMPDT)
间质强度调制光动力疗法 (i-IMPDT)
基本信息
- 批准号:9345250
- 负责人:
- 金额:$ 22.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptionAnatomyArchitectureBladderCancerousCaringCellsClinicalClinical TrialsCodeComputer softwareComputing MethodologiesCoupledCustomCytotoxic ChemotherapyDevelopmentDevelopment PlansDiffuseDoseElementsEsophagealFinite Element AnalysisFluorescenceFutureGeneric DrugsGeometryGoalsHead and Neck CancerLasersLeadLightMalignant - descriptorMalignant NeoplasmsMathematicsMeasurementMeasuresMethodologyMethodsModelingModificationMolecularMonitorMouth NeoplasmsOpticsOrganOxygenPUVA PhotochemotherapyPatient-Focused OutcomesPatientsPerformancePhasePhotobleachingPhotosensitizationPhotosensitizing AgentsPhysiciansPremalignantPropertyRadiation therapyReactive Oxygen SpeciesResearch PersonnelRoswell Park Cancer InstituteRunningSinglet OxygenSmall Business Innovation Research GrantSourceSource CodeSurfaceSystemTechniquesTimeTissuesToxic effectTreatment-Related CancerTumor OxygenationTumor TissueWorkabsorptionbasecancer therapycell killingcostdosimetryeffective therapyhead and neck cancer patientimprovedindividualized medicineinterstitiallight scatteringmulticore processoropen sourceoptical fiberprototypeshared memorysimulationskin lesionsoftware developmenttherapy developmenttherapy outcometooltreatment planningtumor
项目摘要
Over 500,000 worldwide cases of head and neck (H&N) cancer occur annually. Despite aggressive
treatment, about 40% of H&N cancers recur and progress. Recent studies of interstitial PDT (I-PDT) have
shown promising results in the treatment of patients with locally advanced H&N cancer that fail standard
therapies. I-PDT provides a means to treat cancerous tumors while minimizing damage to surrounding
tissues and does not exhibit cumulative cell toxicities, distinguishing it from radiation therapy. However, the
recent I-PDT studies do not use pre-treatment planning nor treatment monitoring with real time light
dosimetry to guide the therapy. As compared to radiation therapy, treatment planning and monitoring for I-
PDT remain rudimentary since patient- and tumor-specific photokinetics factors such as tumor oxygenation,
photosensitizer (PS) levels and singlet oxygen dose that are critical to the delivery of effective treatment
doses are not taken into account. The development of treatment planning and monitoring tools that take into
account these factors will fill an unmet clinical need and provide for individualized patient treatment. An
effective I-PDT treatment planning and monitoring system is expected to improve therapeutic outcomes,
reduce the need for repeat I-PDT or additional cell-killing therapy, and could therefore reduce overall costs
in the per patient delivery of cancer-related therapy and care. This SBIR Phase I proposal will be done by
Simphotek, Inc. with a subcontract to Roswell Park Cancer Institute (RPCI). The major objective is to
develop new prototype software and hardware tools to enable interstitial Intensity-Modulated Photodynamic
Therapy (i-IMPDT). The new tools will combine simulations of PS photokinetics with light propagation using
fast finite element (FE) analysis techniques that include light scattering and absorption. In the future, these
tools will create a platform to provide real time treatment guidance and dose modifications during I-PDT.
Simphotek is a world leader in developing sophisticated photokinetics software and RPCI is a world leader
in the fields of I-PDT and FE analysis of H&N cancers. This Phase I SBIR has three major aims. Aim 1 is to
develop and confirm the accuracy of new customized FE software code and hardware tools to calculate the
light dose for I-PDT. To determine simulation accuracy, calculations using the new tools will be compared to
phantom measurements done at RPCI mimicking the anatomy of H&N cancer patients. Aim 2 is to adapt
Simphotek's photokinetics code to calculate PS fluorescence, PS photobleaching, PS concentration and
singlet oxygen dose. Aim 3 is to determine the feasibility of combining the new FE code and the modified
photokinetics software code into a unified platform code. After initial development in Phase I, the prototype
treatment planning and monitoring tools will be further advanced in Phase II. Clinical trials will be performed
in Phase III to determine if the platform code and hardware provides I-PDT physicians and researchers with
accurate light dose distributions in cancer tumors and improves patient outcomes.
全世界每年发生超过50万例头颈部(H&N)癌症病例。尽管进行了积极
治疗后,约40%的H&N癌症复发和进展。间质PDT(I-PDT)的最新研究
在治疗局部晚期H&N癌症患者方面显示出有希望的结果,
治疗I-PDT提供了一种治疗癌性肿瘤的方法,同时最大限度地减少对周围环境的损害。
组织,并且不表现出累积的细胞毒性,将其与放射治疗区分开来。但
最近的I-PDT研究不使用治疗前计划,也不使用具有真实的时间光的治疗监测
剂量测定来指导治疗。与放射治疗相比,I-
PDT仍然是基本的,因为患者和肿瘤特异性光动力学因素,如肿瘤氧合,
光敏剂(PS)水平和单线态氧剂量对有效治疗的递送至关重要
剂量没有考虑在内。制定治疗计划和监测工具,
考虑到这些因素将填补未满足的临床需求,并提供个性化的患者治疗。一个
有效的I-PDT治疗计划和监测系统有望改善治疗结果,
减少重复I-PDT或额外的细胞杀伤治疗的需要,因此可以降低总成本
癌症相关治疗和护理的患者数量。SBIR第一阶段提案将由
Simphotek,Inc.罗斯威尔公园癌症研究所(RPCI)主要目标是
开发新的原型软件和硬件工具,以实现间隙强度调制光动力学
治疗(i-IMPDT)。新的工具将结合联合收割机模拟PS光动力学与光传播使用
快速有限元(FE)分析技术,包括光散射和吸收。未来这些
工具将创建一个平台,以在I-PDT期间提供真实的治疗指导和剂量修改。
Simphotek是开发复杂光动力学软件的世界领导者,RPCI是世界领导者
在H&N癌症的I-PDT和FE分析领域。第一阶段SBIR有三个主要目标。目标1是
开发并确认新的定制FE软件代码和硬件工具的准确性,以计算
I-PDT的光剂量。为了确定模拟精度,将使用新工具进行的计算与
在RPCI进行的体模测量,模拟H&N癌症患者的解剖结构。目标二:适应
Simphotek的光动力学代码用于计算PS荧光、PS光漂白、PS浓度和
单线态氧剂量。目的3是确定新的有限元代码和修改后的
将光动力学软件代码转换成统一的平台代码。经过第一阶段的初步开发,
治疗计划和监测工具将在第二阶段得到进一步发展。将进行临床试验
在第三阶段,以确定平台代码和硬件是否为I-PDT医生和研究人员提供
在癌症肿瘤中精确的光剂量分布,并改善患者的治疗效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Evgueni Parilov其他文献
Evgueni Parilov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Evgueni Parilov', 18)}}的其他基金
Development of Novel Fast GPU Monte Carlo and Active Photonics Simulation Softwar
新型快速GPU蒙特卡罗和主动光子学仿真软件的开发
- 批准号:
8780326 - 财政年份:2014
- 资助金额:
$ 22.61万 - 项目类别:
相似海外基金
Linking Epidermis and Mesophyll Signalling. Anatomy and Impact in Photosynthesis.
连接表皮和叶肉信号传导。
- 批准号:
EP/Z000882/1 - 财政年份:2024
- 资助金额:
$ 22.61万 - 项目类别:
Fellowship
Digging Deeper with AI: Canada-UK-US Partnership for Next-generation Plant Root Anatomy Segmentation
利用人工智能进行更深入的挖掘:加拿大、英国、美国合作开发下一代植物根部解剖分割
- 批准号:
BB/Y513908/1 - 财政年份:2024
- 资助金额:
$ 22.61万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Social and ecological influences on brain anatomy
博士论文研究:社会和生态对大脑解剖学的影响
- 批准号:
2235348 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
Standard Grant
Simultaneous development of direct-view and video laryngoscopes based on the anatomy and physiology of the newborn
根据新生儿解剖生理同步开发直视喉镜和视频喉镜
- 批准号:
23K11917 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Computational comparative anatomy: Translating between species in neuroscience
计算比较解剖学:神经科学中物种之间的翻译
- 批准号:
BB/X013227/1 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
Research Grant
computational models and analysis of the retinal anatomy and potentially physiology
视网膜解剖学和潜在生理学的计算模型和分析
- 批准号:
2825967 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
Studentship
Genetics of Extreme Phenotypes of OSA and Associated Upper Airway Anatomy
OSA 极端表型的遗传学及相关上呼吸道解剖学
- 批准号:
10555809 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
Development of a novel visualization, labeling, communication and tracking engine for human anatomy.
开发一种新颖的人体解剖学可视化、标签、通信和跟踪引擎。
- 批准号:
10761060 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
Understanding the functional anatomy of nociceptive spinal output neurons
了解伤害性脊髓输出神经元的功能解剖结构
- 批准号:
10751126 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
The Anatomy of Online Reviews: Evidence from the Steam Store
在线评论剖析:来自 Steam 商店的证据
- 批准号:
2872725 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
Studentship